The Osteoarthritis market report also offers comprehensive insights into the Osteoarthritis market size, share, Osteoarthritis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteoarthritis market size growth forward.
Some of the key highlights from the Osteoarthritis Market Insights Report:
Recent advancements in the osteoarthritis (OA) treatment landscape have introduced promising developments:
Semaglutide for Obesity-Related Knee Osteoarthritis: A study published in late 2024 found that semaglutide, a GLP-1 receptor agonist commonly used for weight management, significantly improved knee pain and physical function in obese patients with knee OA. The 68-week trial showed that semaglutide-treated participants experienced greater weight loss and reduced pain compared to the placebo group, highlighting the drug’s potential for managing OA symptoms alongside obesity.
Stem Cell Therapy (MAG200): Australian biotech company Magellan Stem Cells revealed successful Phase I/II trial results for MAG200, an allogeneic stem cell therapy. This single injection therapy demonstrated significant improvements in joint pain, function, and cartilage quality. It could potentially delay or prevent the need for joint replacement surgery, particularly in younger OA patients.
Non-Invasive Imaging for OA Diagnosis: Advances in imaging technology have enabled more precise diagnostics for OA, facilitating earlier intervention and better treatment personalization. Techniques include high-resolution MRI and quantitative imaging for cartilage assessment, which aid in tracking disease progression and treatment efficacy.
These breakthroughs represent significant strides toward more effective, non-invasive, and sustainable OA management options, targeting not only symptoms but potentially modifying disease progression. Continued research is expected to expand these treatment possibilities.
Several key pharmaceutical companies, including Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis, Kolon Tissuegene, Paradigm Biopharma, Novo Nordisk, Amzell, Nature Cell, Tissuetech, Techfields Pharma, Sorrento Therapeutics, Merck Kgaa/trialspark, Akl Research and Development, Medipost, Medivir, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.
In 2024, the market size of osteoarthritis was highest in the US among the 7MM, accounting for approximately USD 19,000 million, which is further expected to increase by 2034.
Amongst EU4 and the UK, Germany captured the maximum revenue share, followed by Spain and France in 2024.
In 2024, Opioids captured the highest market size of osteoarthritis by therapies, i.e., around USD 9,200 million in the US.
In December 2024, Bioventus agreed to a nationwide contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis pain.
In December 2024, Levicept announced that it had completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent. Top-line data are expected to be announced in the late first half of 2024.
BioSolution is planning to apply for conditional product approval for CARTILIFE from the US FDA in 2024. Currently, Phase II clinical trials are underway in the US, and the last patient is to be administered. The final results are expected to be released as early as the end of 2024.
Many key players are developing cell therapies for OA in various stages of development. If approved, these therapies may provide better treatment options as they can slow disease progression and possibly cure it.
Strategise your business goals by understanding market dynamics @ Osteoarthritis Market Landscape
Osteoarthritis Overview
Osteoarthritis (OA) is the most prevalent form of arthritis, often referred to as degenerative joint disease or “wear-and-tear” arthritis. It commonly affects weight-bearing joints like the knees and feet, as well as joints frequently used in daily activities, such as the hands and hips. Symptoms primarily include joint pain and stiffness, with pain typically worsening during movement or by the end of the day.
OA is a leading cause of disability among older adults and represents a significant societal cost. Its prevalence is increasing due to the aging population and rising obesity rates, both of which are key risk factors contributing to the progression and impact of the disease.
Do you know the treatment paradigms for different countries? Download our Osteoarthritis Market Sample Report
Osteoarthritis Epidemiology Segmentation
DelveInsight’s Osteoarthritis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Osteoarthritis historical patient pools and forecasted Osteoarthritis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Osteoarthritis Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Osteoarthritis Prevalence
Age-Specific Osteoarthritis Prevalence
Gender-Specific Osteoarthritis Prevalence
Diagnosed and Treatable Cases of Osteoarthritis
Visit for more @ Osteoarthritis Epidemiological Insights
Osteoarthritis Treatment Market
Osteoarthritis, also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage; it is most common in the elderly. Several pharmacologic treatments are available to manage knee OA-related pain and improve its functionality.
Common pharmacologic interventions to help alleviate knee OA symptoms include nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids, intra-articular hyaluronic acid, and opioids. The US FDA-approved sodium hyaluronate includes SUPARTZ (Smith & Nephew) – approved on January 24, 2001; ORTHOVISC (Anika Therapeutics) – approved on February 4, 2004; EUFLEXXA (Ferring Pharmaceuticals) – approved in 2005; and GEL-ONE Cross-linked Hyaluronate (Seikagaku Corporation) – approved in 2011. In October 2017, Flexion Therapeutics announced the US FDA approval of ZILRETTA for knee OA. The pivotal Phase III trial, on which the approval of Zilretta was based, showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16.
The current developmental pipeline for knee OA is robust; several companies have initiated clinical trials investigating new treatment options or studying how to use existing treatment options better. The dynamics of the OA market are also anticipated to change in the coming years, owing to the rise in healthcare spending globally.
Osteoarthritis Therapy Assessment
ZILRETTA: Flexion Therapeutics/Pacira BioSciences
ZILRETTA is the first and only extended-release, intra-articular therapy for patients confronting OA knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide, commonly administered, immediate-release corticosteroid – with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase III trial, on which the approval of Zilretta was based, showed that Zilretta significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. In October 2017, Flexion Therapeutics announced the US FDA approval of Zilretta, the first and only extended-release, intra-articular injection for knee OA. In November 2022, the company announced the launch of Phase III study in shoulder OA in 2024 and anticipated completion of study by 1H 2024.
CINGAL: Anika Therapeutics
CINGAL is the first and only commercially available combination viscosupplement and is currently being used successfully by physicians to provide rapid and long-lasting relief from pain and discomfort caused by OA for patients in a growing number of countries. CINGAL is a patented formulation composed of the company’s proprietary crosslinked sodium hyaluronate and triamcinolone hexacetonide. CINGAL is Anika’s third-generation viscosupplement to treat pain associated with knee OA, following its other products, Orthovisc and Monovisc. In June 2016, Anika Therapeutics announced the commercial launch of CINGAL in the European Union. In November 2022, company announced positive Phase III data of CINGAL 19-01 study, as per the company statement it plans meeting with FDA to discuss next steps for the US regulatory approval. Moreover the company is actively assessing options to advance CINGAL, including potential commercial partnerships in the US and select Asian markets.
TRIVISC: OrthogenRx / Avanos Medical
TRIVISC is from a class of products known as hyaluronic acid, sodium hyaluronate, or hyaluronan (HA), also referred to as viscosupplementation therapy. It is used in a nonsurgical procedure that helps supplement the viscous properties of the fluid in the knee joint. In November 2017, the company announced that the US FDA had approved TRIVISC for the treatment of knee OA in patients who failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics.
VISCO-3: Zimmer Biomet/Seikagaku Corporation
VISCO-3 is a solution made of highly purified sodium hyaluronate. Hyaluronan is a natural chemical found in the body and is found in particularly high amounts in joint tissues and in the fluid (synovial fluid) that fills the joints. In December 2015, Seikagaku Corporation (Tokyo) announced that the US FDA had approved VISCO-3 for the treatment of knee OA in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Osteoarthritis Key Companies
Biosplice Therapeutics
Gilead Sciences
Flexion Therapeutics
GlaxoSmithKline
Levicept
Arthrogen
Personalized Stem Cells
Peptinov
Asahi Kasei Pharma
Taiwan Bio Therapeutics
OliPass Corporation
Bioventus
Medipost
Moebius Medical
ReqMed
TissueTech
Novartis
AstraZeneca
Cynata Therapeutics
Bone Therapeutics S.A
Regeneron Pharmaceuticals
Techfields Pharma
Ampio Pharmaceuticals
Taiwan Liposomal Company
K-STEMCELL
Stempeutics
Levolta Pharmaceuticals
For more information, visit Osteoarthritis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Osteoarthritis Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Osteoarthritis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Osteoarthritis epidemiology in the 7MM
Osteoarthritis marketed and emerging therapies
Osteoarthritis companies
Osteoarthritis market drivers and barriers
Key Questions Answered in the Osteoarthritis Market Report 2034:
What was the Osteoarthritis market share distribution in 2020, and how would it appear in 2034?
What is the total Osteoarthritis market size and the market size by therapy across the 7MM for the study period (2020-34)?
What are the important findings from 7MM, and which country will have the greatest Osteoarthritis market size from 2020-34?
During the study period (2020-2034), at what CAGR is the Osteoarthritis market projected to expand at 7MM?
Table of Contents:
1 Osteoarthritis Market Key Comprehensive Insights
2 Osteoarthritis Market Report Introduction
3 Competitive Intelligence Analysis for Osteoarthritis
4 Osteoarthritis Market Analysis Overview at a Glance
5 Executive Summary of Osteoarthritis
6 Osteoarthritis Epidemiology and Market Methodology
7 Osteoarthritis Epidemiology and Patient Population
8 Osteoarthritis Patient Journey
9 Osteoarthritis Treatment Algorithm, Osteoarthritis Current Treatment, and Medical Practices
10 Key Endpoints in Osteoarthritis Clinical Trials
11 Osteoarthritis Marketed Therapies
12 Osteoarthritis Emerging Therapies
13 Osteoarthritis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Osteoarthritis
16 Osteoarthritis Market Key Opinion Leaders Reviews
18 Osteoarthritis Market Drivers
19 Osteoarthritis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Osteoarthritis Epidemiology 2034
DelveInsight’s “Osteoarthritis – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Osteoarthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Osteoarthritis Pipeline 2024
“Osteoarthritis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Osteoarthritis market. A detailed picture of the Osteoarthritis pipeline landscape is provided, which includes the disease overview and Osteoarthritis treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
